CV Stock Summary and Trading Ideas (Capsovision | NASDAQ:CV)

CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.

Capsovision trades on the NASDAQ stock market under the symbol CV.

As of December 12, 2025, CV stock price declined to $12.85 with 322,030 million shares trading.

CV has a beta of 1.53, meaning it tends to be more sensitive to market movements. CV has a correlation of 0.09 to the broad based SPY ETF.

CV has a market cap of $601.94 million. This is considered a Small Cap stock.

Last quarter Capsovision reported $4 million in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-152,100 and missed earnings estimates by -$.04.

The top ETF exchange traded funds that CV belongs to (by Net Assets): IWO, IWC, VTWO, VXF, RSSL.

CV support price is $13.37 and resistance is $15.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CV shares will trade within this expected range on the day.